



147 Rec'd PCT/PTO 06 MAR 2006

PCT

Docket No.: A0345.0017  
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Olivier Bezencon et al.

Application No.: 10/554,704<sup>5382</sup>

Confirmation No.: @@@

Filed: October 27, 2005

Art Unit: N/A

For: NOVEL TROPANE DERIVATIVES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Timing of Filing of the Information Disclosure Statement:

- ☒ This IDS is being filed before the First Office Action<sup>1</sup>.
- ☐ This IDS is being filed after the issuance of the First Office Action but before the issuance of a Final Office Action<sup>2</sup>.

<sup>1</sup> The IDS should, where possible, include a certification under 37 C.F.R. §1.97(e).

<sup>2</sup> The IDS *must* include *either* a certification under 37 C.F.R. §1.97(e) *or* the fee set forth in 37 C.F.R. §1.17(p).

- ☐ This IDS is being filed after the issuance of a Final Office Action, Ex Parte Quayle Action or Notice of Allowance but before the payment of the Final Fee<sup>3</sup>.

**Certifications:**

If checked, the undersigned makes the following statement(s):

- ☐ Statement under 37 CFR § 1.97(e):

Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement; or

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

- ☐ Statement Under 37 C.F.R. § 1.704(d):

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application less than thirty days prior to the filing of this information disclosure statement.

**Fee Required by 37 C.F.R. § 1.97(c)(2) or 1.97(d)(2):**

- ☐ If checked, the fee of \$180.00 set forth in 37 C.F.R. §1.17(p) is attached.

---

<sup>3</sup> The IDS *must* include *both* a certification under 37 C.F.R. §1.97(e) *and* the fee set forth in 37 C.F.R. §1.17(p).

**Copies of Information:**

In accordance with 37 C.F.R. §1.98(a), the following are enclosed:

- ☒ A legible copy<sup>4</sup> of each document (or relevant portion thereof) cited in the attached PTO/SB/08, except for U.S. patent and U.S. published applications.
- ☐ With respect to any information which is not in English, a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, is attached. This concise explanation is provided by way of:
- ☐ A translation of the relevant portions of the non-English language information<sup>5</sup>;
  - ☐ A statement explaining the relevant portions of the non-English language information;
  - ☐ A copy [and, where not in the English language, a translation] of at least the relevant portion(s)<sup>6</sup> of the communication from a foreign patent office in a counterpart foreign application in which the information was cited; or
  - ☐ This information is contained in the specification of the present application.

---

<sup>4</sup> A legible copy of the document is not required if (1) the information was previously cited by, or submitted to, the Office and considered by the Office in a prior U.S. application to which this application claims priority, provided that the prior application is properly identified in this IDS, and (2) the IDS submitted in the earlier application complies with 37 C.F.R. § 1.98(a) – (c). This exception does not apply to information cited in an International Application.

<sup>5</sup> 37 C.F.R. §1.98(a)(3)(ii) *requires* that an English language translation be provided when a translation of the document, or portion thereof, "is within the possession, custody or control of, or is readily available to any individual designated in 37 C.F.R. § 1.56(c)."

<sup>6</sup> The relevant portion is that portion which indicates the degree of relevance found by the foreign patent office. This may be an explanation of which portion of the of the reference is particularly relevant, to which claims it applies, or merely an "X", "Y", or "A" indication on a search report. MPEP §609 III A(3).

☒ In accordance with 37 C.F.R. 1.98(d), copies of the cited documents are not enclosed as they were provided in application Serial No. 10/513,103 , filed October 29, 2004, which the present application relies upon for an earlier effective filing date under 35 U.S.C. 120.

**Materiality:**

Whether or not the information and references disclosed in this Information Disclosure Statement is "material" pursuant to 37 CFR 1.56, this submission is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

In the event the actual fee is inadvertently not enclosed or if any additional fee during the prosecution of this application is not paid, the Patent Office is authorized to charge the underpayment to Deposit Account No. 50-2215.

Dated: March 6, 2006

Respectfully submitted,

By \_\_\_\_\_

Charles E. Miller

Registration No.: 27,576

DICKSTEIN SHAPIRO MORIN &

OSHINSKY LLP

1177 Avenue of the Americas, 41<sup>st</sup> Floor

New York, NY 10036-2714

(212) 835-1400



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>Substitute for form 1449A/B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/555,382
				Filing Date	October 27, 2005
				First Named Inventor	Olivier Bezencon
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	A0345.00167

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,380,758			
	AB	US-5,703,073			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number-Kind Code <sup>2</sup> (if known)			
	BA		WO-97/27749	08-07-1997	Nitromed Inc.	
	BB		WO-98/19672	05-14-1998	Nitromed Inc.	
	BC		WO-98/21193	05-22-1998	Nicox S.A.	
	BD		WO-99/00361	01-07-1999	Nicox S.A.	
	BE*		WO-97/09311			
	BF*		WO-03/093267			
	BG*		WO-04/002957			
	BH		WO-0022153	04-20-2000	Lonza AG	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFV. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CA	Shigeru Oae, et al., "ORGANIC THIONITRITES AND RELATED SUBSTANCES," Organic Preparations and Procedures Int., (1983), pp. 165-198		
	CB	Guido Vogel, et al., "1(3),2-Diacylglycerol-3(1)-O-2'-(hydroxymethyl)(N,N,N-tri-methyl)-β-alanine (DGTA): A novel betaine lipid from Ochromonas danica (Chrysophyceae)" Chemistry and Physics of Lipids, (1990), pp. 99-109		
	CC	Dieter Seebach, et al., "123. 1,3-Dioxanone Derivatives from β-Hydroxy-carboxylic Acids an Pivalaldehyde. Versatile Building Blocks for Syntheses of Enantiomerically Pure Compounds. A Chiral Acetoacetic Acid Derivative," Helvetica Chimica Acta, vol. 69 (1986), pp. 1147-1152		
	CD	Stephen P. Gotzo, et al., "Preparation of (R)- and (S)-3-Hydroxy-2-(trifluoromethyl)propionic Acid by Resolution with (R,R)- and (S,S)-2-Amino-1-phenylpropane-1,3-diol." Chimia, (1996), pp 20-23		
	CE	Samia A. El-Abbady, et al., "ENHANCED REACTIVITY OF PYRIDINE-3-OL TOWARDS 4-PHENYL-1,2,4-TRIAZOLINE-3,5-DIONE: FMO TREATMENT OF THE CYCLOADDITION PROCESS BY ASE-D-MO CALCULATIONS METHOD," Zagazig J. Pharm. Sci., (1996), vol. 5, pp. 68-74		
	CF*	Waeber B., et al., "THE RENIN-ANGIOTENSIN SYSTEM IN EXPERIMENTAL AND HUMAN HYPERTENSION", in Berkenhager W.H. Reid J.L. (eds): Hypertension, Amsterdam, Elsevier Science Publishing Co., (1996), pp. 489-519		
	CG*	Weber, M.A., Am. J. Hypertens., (1992), 5, 247S		
Examiner Signature				Date Considered



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/555,382
				Filing Date	October 27, 2005
				First Named Inventor	Olivier Bezencon
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	A0345.00167

CH*	Rosenberg, M.E., et al., Kidney International, (1994), 45, 403	
CI*	Breyer, J.A., et al., Kidney International, (1994), 45, S156	
CJ*	Vaughan, D.E., et al., Cardiovasc. Res., (1994), 28, 159	
CK*	Fouad-Tarazi, F., et al., Am. J. Med., (1988), 84 (Suppl. 3A), 83	
CL*	Pfeffer, M.A., et al., N. Engl. J. Med., (1992), 327, 669	
CM*	Kleinert, H.D., Cardiovasc. Drugs, (1995), 9, 645	
CN*	Husain, A., J. Hypertens., (1993), 11, 1155	
CO*	Israïli Z.H., et al., Annals of Internal Medicine, (1992), 117, 234	
CP*	Azizi M., et al., J. Hypertens., (1994) 12, 419	
CQ*	Neutel, J.M., et al., Am. Heart, (1991), 122, 1094	
CR*	Rahuel, Jr., et al., Chem. Biol., (2000), 7, 493	
CS*	Mealy, N.E., Drugs of the Future, (2001) 26, 1139	
CT*	Oefner, C., et al., Chem. Biol., (1999), 6, 127	
CU*	Marki, H.P., et al., Il Farmaco, (2001), 56, 21	
CV*	Majewski, M., et al., J. Org. Chem., (1995) 60, 5825	
CW*	Kiesewetter, D.O., Tetrahedron Asymmetry, (1993) 4, 2183	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--